Last reviewed · How we verify
Omeprazole tablet dosing
Omeprazole tablet dosing is a Small molecule drug developed by AstraZeneca. It is currently in Phase 1 development.
Omeprazole is a small molecule that inhibits the potassium-transporting ATPase, a proton pump in the stomach lining. The typical dosing of omeprazole tablets is not specified in the provided facts, but it is used to treat various conditions, including gastroesophageal reflux disease, which is not mentioned in the facts, but is a common indication for omeprazole.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
AstraZeneca is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Omeprazole tablet dosing |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Drug Interaction Study on Linaprazan Glurate Capsules (PHASE1)
- A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis (PHASE1)
- Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors (PHASE1)
- A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants (PHASE1)
- Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects (PHASE1)
- Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects (PHASE1)
- A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults (PHASE1)
- Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omeprazole tablet dosing CI brief — competitive landscape report
- Omeprazole tablet dosing updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Omeprazole tablet dosing
What is Omeprazole tablet dosing?
Who makes Omeprazole tablet dosing?
What development phase is Omeprazole tablet dosing in?
Related
- Manufacturer: AstraZeneca — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing